In force Publication date 29 Sep 16
Analysis of antibody-based myostatin inhibitors
Project Title: Analysis of antibody-based myostatin inhibitors
Researchers: Pr. M. Thevis, Pr. W. Schänzer, Dr. K. Walpurgis
Institution: German Sport University, Germany
Year accepted: 2014
Summary: The aim of the planned project is to establish a detection method for MYO-029 (Stamulumab), a recombinant human myostatin antibody which was developed by Wyeth Pharmaceuticals in 2005. MYO-029 specifically blocks myostatin signaling by preventing the interaction between the growth factor and its target receptor.
Available in 1 language.